Related references
Note: Only part of the references are listed.Molecular bottlebrush prodrugs as mono- and triplex combination therapies for multiple myeloma (vol 18, pg 184, 2023)
Alexandre Detappe et al.
NATURE NANOTECHNOLOGY (2023)
Cancer statistics, 2022
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2022)
AXL/MERTK inhibitor ONO-7475 potently synergizes with venetoclax and overcomes venetoclax resistance to kill FLT3- ITD acute myeloid leukemia
Sean M. Post et al.
HAEMATOLOGICA (2022)
A guide to machine learning for biologists
Joe G. Greener et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2022)
Current and emerging pharmacotherapy for the treatment of childhood acute myeloid leukemia
Branko Cuglievan et al.
EXPERT OPINION ON PHARMACOTHERAPY (2022)
Venetoclax synergizes with gilteritinib in FLT3 wild-type high-risk acute myeloid leukemia by suppressing MCL-1
Maike Janssen et al.
BLOOD (2022)
Relapsed acute myeloid leukemia in children and adolescents: current treatment options and future strategies
Sara Zarnegar-Lumley et al.
LEUKEMIA (2022)
Poor outcome of pediatric patients with acute myeloid leukemia harboring high FLT3/ITD allelic ratios
Kun-Yin Qiu et al.
NATURE COMMUNICATIONS (2022)
Principal component analysis
Michael Greenacre et al.
NATURE REVIEWS METHODS PRIMERS (2022)
The Use of Phospholipids to Make Pharmaceutical Form Line Extensions
Peter van Hoogevest et al.
EUROPEAN JOURNAL OF LIPID SCIENCE AND TECHNOLOGY (2021)
Liposome composition in drug delivery design, synthesis, characterization, and clinical application
Danielle E. Large et al.
ADVANCED DRUG DELIVERY REVIEWS (2021)
How I treat pediatric acute myeloid leukemia
Jeffrey E. Rubnitz et al.
BLOOD (2021)
The role of liposomes in clinical nanomedicine development. What now? Now what?
Daan J. A. Crommelin et al.
JOURNAL OF CONTROLLED RELEASE (2020)
Development and validation of a sensitive UHPLC-MS/MS analytical method for venetoclax in mouse plasma, and its application to pharmacokinetic studies
Eric D. Eisenmann et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2020)
Phase I/II Study of CPX-351 Followed by Fludarabine, Cytarabine, and Granulocyte-Colony Stimulating Factor for Children With Relapsed Acute Myeloid Leukemia: A Report From the Children's Oncology Group
Todd M. Cooper et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
MERTK in cancer therapy: Targeting the receptor tyrosine kinase in tumor cells and the immune system
Justus M. Huelse et al.
PHARMACOLOGY & THERAPEUTICS (2020)
Pharmacokinetics, drug metabolism, and tissue distribution of CPX-351 in animals
Qi Wang et al.
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE (2020)
Rapid Assembly and Screening of Multivalent Immune Cell-Redirecting Therapies for Leukemia
Priscilla Do et al.
ACS COMBINATORIAL SCIENCE (2020)
Synergistic effect of BCL2 and FLT3 co-inhibition in acute myeloid leukemia
Lindsey T. Brinton et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
Enhancing chemotherapy response through augmented synthetic lethality by co-targeting nucleotide excision repair and cell-cycle checkpoints
Yi Wen Kong et al.
NATURE COMMUNICATIONS (2020)
Ex vivo cultures and drug testing of primary acute myeloid leukemia samples: Current techniques and implications for experimental design and outcome
D. G. J. Cucchi et al.
DRUG RESISTANCE UPDATES (2020)
LC-Q-TOF-MS driven identification of potential degradation impurities of venetoclax, mechanistic explanation on degradation pathway and establishment of a quantitative analytical assay method
Dhruvisha Pokar et al.
JOURNAL OF ANALYTICAL SCIENCE AND TECHNOLOGY (2020)
In Vivo Evaluation of Dual-Targeted Nanoparticles Encapsulating Paclitaxel and Everolimus
Loujin Houdaihed et al.
CANCERS (2019)
Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia
Jun Ma et al.
CLINICAL CANCER RESEARCH (2019)
Outcome of Infants Younger Than 1 Year With Acute Lymphoblastic Leukemia Treated With the Interfant-06 Protocol: Results From an International Phase III Randomized Study
Rob Pieters et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia
Courtney D. DiNardo et al.
BLOOD (2019)
FDA Approval Summary: (Daunorubicin and Cytarabine) Liposome for Injection for the Treatment of Adults with High-Risk Acute Myeloid Leukemia
Aviva C. Krauss et al.
CLINICAL CANCER RESEARCH (2019)
Targeting FLT3 mutations in AML: review of current knowledge and evidence
Naval Daver et al.
LEUKEMIA (2019)
Binary Targeting of siRNA to Hematologic Cancer Cells In Vivo Using Layer-by-Layer Nanoparticles
Ki Young Choi et al.
ADVANCED FUNCTIONAL MATERIALS (2019)
Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study
Courtney L. DiNardo et al.
LANCET ONCOLOGY (2018)
FLT3-ITD and its current role in acute myeloid leukaemia
Francisco Alejandro Lagunas-Rangel et al.
MEDICAL ONCOLOGY (2017)
Rationally Designed 2-in-1 Nanoparticles Can Overcome Adaptive Resistance in Cancer
Aaron Goldman et al.
ACS NANO (2016)
Prognostic significance of FLT3-ITD in pediatric acute myeloid leukemia: a meta-analysis of cohort studies
Xiaoli Wu et al.
MOLECULAR AND CELLULAR BIOCHEMISTRY (2016)
Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia
Marina Konopleva et al.
CANCER DISCOVERY (2016)
The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia
Katherine A. Minson et al.
JCI INSIGHT (2016)
Obatoclax is a direct and potent antagonist of membrane-restricted Mcl-1 and is synthetic lethal with treatment that induces Bim
Mai Nguyen et al.
BMC CANCER (2015)
Tumor-Targeted Synergistic Blockade of MAPK and PI3K from a Layer-by-Layer Nanoparticle
Erik C. Dreaden et al.
CLINICAL CANCER RESEARCH (2015)
Efficacy of a Mer and Flt3 tyrosine kinase small molecule inhibitor, UNC1666, in acute myeloid leukemia
Alisa B. Lee-Sherick et al.
ONCOTARGET (2015)
Intensified Chemotherapy Without Sct in Infant All: Results From COG P9407 (Cohort 3)
ZoAnn E. Dreyer et al.
PEDIATRIC BLOOD & CANCER (2015)
Analysis of drug combinations: current methodological landscape
Julie Foucquier et al.
PHARMACOLOGY RESEARCH & PERSPECTIVES (2015)
UNC2025, a Potent and Orally Bioavailable MER/FLT3 Dual Inhibitor
Weihe Zhang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
A Nanoparticle-Based Combination Chemotherapy Delivery System for Enhanced Tumor Killing by Dynamic Rewiring of Signaling Pathways
Stephen W. Morton et al.
SCIENCE SIGNALING (2014)
The TAM family: phosphatidylserine-sensing receptor tyrosine kinases gone awry in cancer
Douglas K. Graham et al.
NATURE REVIEWS CANCER (2014)
Layer-by-Layer Nanoparticles for Systemic Codelivery of an Anticancer Drug and siRNA for Potential Triple-Negative Breast Cancer Treatment
Zhou J. Deng et al.
ACS NANO (2013)
Understanding synergy
Nori Geary
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2013)
Mer receptor tyrosine kinase is a therapeutic target in pre-B-cell acute lymphoblastic leukemia
Rachel M. A. Linger et al.
BLOOD (2013)
Genomic impact of transient low-dose decitabine treatment on primary AML cells
Jeffery M. Klco et al.
BLOOD (2013)
Improved Outcome in Pediatric Relapsed Acute Myeloid Leukemia: Results of a Randomized Trial on Liposomal Daunorubicin by the International BFM Study Group
Gertjan J. L. Kaspers et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Mer or Axl receptor tyrosine kinase inhibition promotes apoptosis, blocks growth and enhances chemosensitivity of human non-small cell lung cancer
R. M. A. Linger et al.
ONCOGENE (2013)
Aberrant Mer receptor tyrosine kinase expression contributes to leukemogenesis in acute myeloid leukemia
A. B. Lee-Sherick et al.
ONCOGENE (2013)
Multicellular Tumor Spheroids for Evaluation of Cytotoxicity and Tumor Growth Inhibitory Effects of Nanomedicines In Vitro: A Comparison of Docetaxel-Loaded Block Copolymer Micelles and Taxotere®
Andrew S. Mikhail et al.
PLOS ONE (2013)
GDC-0941, a Novel Class I Selective PI3K Inhibitor, Enhances the Efficacy of Docetaxel in Human Breast Cancer Models by Increasing Cell Death In Vitro and In Vivo
Jeffrey J. Wallin et al.
CLINICAL CANCER RESEARCH (2012)
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Jordi Barretina et al.
NATURE (2012)
Pharmacogenomics in pediatric leukemia
Steven W. Paugh et al.
CURRENT OPINION IN PEDIATRICS (2010)
Long-term results of the children's cancer group studies for childhood acute lymphoblastic leukemia 1983-2002: A Children's Oncology Group Report
P. S. Gaynon et al.
LEUKEMIA (2010)
Leukemia-selective uptake and cytotoxicity of CPX-351, a synergistic fixed-ratio cytarabine:daunorubicin formulation, in bone marrow xenografts
Wah-Seng Lim et al.
LEUKEMIA RESEARCH (2010)
Outcome for Children Treated for Relapsed or Refractory Acute Myelogenous Leukemia (rAML): A Therapeutic Advances in Childhood Leukemia (TACL) Consortium Study
Matthew F. Gorman et al.
PEDIATRIC BLOOD & CANCER (2010)
BCL-2 family antagonists for cancer therapy
Guillaume Lessene et al.
NATURE REVIEWS DRUG DISCOVERY (2008)
Machine learning and its applications to biology
Adi L. Tarca et al.
PLOS COMPUTATIONAL BIOLOGY (2007)
Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system
S Sengupta et al.
NATURE (2005)
Mer receptor tyrosine kinase signaling.: Prevention of apoptosis and alteration of cytoskeletal architecture without stimulation or proliferation.
KL Guttridge et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Neural networks for classification: A survey
GQP Zhang
IEEE TRANSACTIONS ON SYSTEMS MAN AND CYBERNETICS PART C-APPLICATIONS AND REVIEWS (2000)
Share Paper
